| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0269881105057515 |
| P8608 | Fatcat ID | release_qvzqysmxbnegxet3zwsmidkfga |
| P698 | PubMed publication ID | 16174674 |
| P5875 | ResearchGate publication ID | 7588598 |
| P2093 | author name string | Callum Livingstone | |
| Hagan Rampes | |||
| P2860 | cites work | Prevalence and Trends in Obesity Among US Adults, 1999-2000 | Q22253005 |
| Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla | Q28367660 | ||
| Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI. | Q30977527 | ||
| Aquaporin-2 as a biomarker of distal renal tubular function using lithium as an experimental model | Q33693214 | ||
| Drug-induced diabetes insipidus: incidence, prevention and management | Q33804457 | ||
| The many roles of the calcium-sensing receptor in health and disease. | Q33861171 | ||
| Lithium-associated clinical hypothyroidism. Prevalence and risk factors | Q33902805 | ||
| Treatment of lithium-induced diabetes insipidus with amiloride | Q33965325 | ||
| Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy | Q34173850 | ||
| The use of lithium in the medically ill. | Q38146344 | ||
| Lithium and body weight gain. | Q40453474 | ||
| Mitogenic effect of lithium in FRTL-5 cells can be reversed by blocking de novo cholesterol synthesis and subsequent signal transduction | Q40880443 | ||
| Lithium induced polyuria and renal vasopressin receptor density | Q41209517 | ||
| Genistein but not staurosporine can inhibit the mitogenic signal evoked by lithium in rat thyroid cells (FRTL-5). | Q41433456 | ||
| Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints | Q42211229 | ||
| Lithium, polyuria and abnormal diurnal weight gain in psychosis | Q42211230 | ||
| Treatment of resistant lithium-induced nephrogenic diabetes insipidus and schizoaffective psychosis with carbamazepine | Q42248476 | ||
| Effect of lithium on deoxyribonucleic acid synthesis and iodide uptake in porcine thyroid cells in culture | Q42479207 | ||
| Lithium stimulates the release of human parathyroid hormone in vitro | Q42518734 | ||
| Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal | Q42551410 | ||
| Renal function on and off lithium in patients treated with lithium for 15 years or more. A controlled, prospective lithium-withdrawal study | Q42555818 | ||
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 | ||
| Lithium-induced nephrogenic diabetes insipidus in older people | Q43709905 | ||
| The course of thyroid abnormalities during lithium treatment: a two-year follow-up study | Q43829982 | ||
| Ten-year follow-up of thyroid function in lithium patients. | Q43837424 | ||
| Thyroid echogenicity in manic-depressive patients receiving lithium therapy | Q44061534 | ||
| Goiter in a newborn exposed to lithium in utero | Q44193230 | ||
| Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI | Q44653156 | ||
| Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium | Q44730844 | ||
| Stabilization of microtubules by lithium ion | Q45010054 | ||
| The molecular basis of nephrogenic diabetes insipidus | Q45887156 | ||
| The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. | Q46088423 | ||
| Relation of body fat distribution to ischemic heart disease. The National Health and Nutrition Examination Survey I (NHANES I) Epidemiologic Follow-up Study | Q46141820 | ||
| Endocrine effects of lithium carbonate in healthy premenopausal women: relationship with body weight regulation | Q47247706 | ||
| Lithium carbonate and weight gain | Q47289121 | ||
| Fat cell number and weight gain in lithium treated patients | Q47339749 | ||
| Lithium treatment and weight gain | Q47341854 | ||
| Lithium administration affects gene expression of thyroid hormone receptors in rat brain | Q48197419 | ||
| Effects of lithium treatment on hypothalamic-pituitary-thyroid axis: a longitudinal study | Q48305793 | ||
| Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. | Q50592736 | ||
| High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. | Q51957863 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 347-355 | |
| P577 | publication date | 2005-09-20 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Lithium: a review of its metabolic adverse effects | |
| P478 | volume | 20 |
| Q34614432 | Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. |
| Q90295312 | Characterization of Calcium Homeostasis in Lithium-Treated Patients Reveals Both Hypercalcaemia and Hypocalcaemia |
| Q43254867 | Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients |
| Q34503303 | Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder? |
| Q39404106 | Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options |
| Q38016176 | Endocrine disturbances related to the use of lithium |
| Q64067761 | Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease |
| Q33702416 | GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity |
| Q47616753 | How Trace Element Levels of Public Drinking Water Affect Body Composition in Turkey |
| Q33602939 | How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications |
| Q57221274 | Hypercalcemia and diabetes insipidus in a patient previously treated with lithium |
| Q39066912 | Improving lithium therapeutics by crystal engineering of novel ionic cocrystals |
| Q46806781 | Ketamine followed by memantine for the treatment of major depression |
| Q38724561 | LISPRO mitigates β-amyloid and associated pathologies in Alzheimer's mice. |
| Q47853128 | Lithium Treatment Aggregates the Adverse Effects on Erythrocytes Subjected to Arsenic Exposure |
| Q92502227 | Lithium for Fracture Treatment (LiFT): a double-blind randomised control trial protocol |
| Q37404584 | Lithium therapy and hyperparathyroidism: an evidence-based assessment |
| Q47279229 | Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management. |
| Q37924185 | Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy |
| Q36755384 | Lithium-induced sinus node disease at therapeutic concentrations: linking lithium-induced blockade of sodium channels to impaired pacemaker activity |
| Q36703683 | Lithium-induced sinus node dysfunction at therapeutic levels |
| Q42286640 | Lithium-induced transient euthyroid hyperthyroxinemia: a case report |
| Q22241779 | Lithium: the pharmacodynamic actions of the amazing ion |
| Q33431424 | Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring |
| Q37488179 | Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety |
| Q92994549 | Managing polyuria during lithium treatment: a preliminary prospective observational study |
| Q39161509 | Medical Co-morbidities Among Patients with Severe Mental Illnesses in a Community Health Facility in Nigeria |
| Q37157389 | NR2B subunit of the NMDA glutamate receptor regulates appetite in the parabrachial nucleus |
| Q34598000 | Parameters for lithium treatment are critical in its enhancement of fracture-healing in rodents |
| Q43144278 | Potentiation of Endocrine Adverse Effects of Lithium by Enalapril and Verapamil |
| Q39152568 | Risk factors for polyuria in a cross-section of community psychiatric lithium-treated patients |
| Q92993194 | Safety monitoring of treatment in bipolar disorder in a tertiary care setting in Sri Lanka and recommendations for improved monitoring in resource limited settings |
| Q36588842 | Sinus Node Dysfunction After Acute Lithium Treatment at Therapeutic Levels |
| Q36599475 | Spectrum of lithium induced thyroid abnormalities: a current perspective |
| Q33715759 | Standards of lithium monitoring in mental health trusts in the UK |
| Q48895126 | Staying at the crossroads: assessment of the potential of serum lithium monitoring in predicting an ideal lithium dose |
| Q27695661 | Structural elucidation of the binding site and mode of inhibition of Li(+) and Mg(2+) in inositol monophosphatase |
| Q36096615 | Subthreshold bipolarity: diagnostic issues and challenges |
| Q57213107 | Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism |
| Q98226384 | The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic acid |
| Q37990676 | The science and practice of lithium therapy |
| Q33854877 | Thyroid Function and Ultrasonography Abnormalities in Lithium-Treated Bipolar Patients: A Cross-sectional Study with Healthy Controls. |
| Q37690833 | Thyroid dysfunction in major psychiatric disorders in a hospital based sample |
| Q35130991 | Thyroid functions and bipolar affective disorder |
| Q98894942 | Thyroid hormone levels and Thyroid Hormone Levels and Ultrasonographic Changes in the Thyroid Gland of Patients on Long-Term Lithium Treatment for Affective Disorders: A Controlled Study |
| Q34504189 | Trace elements in glucometabolic disorders: an update |
| Q37067704 | Weight gain and metabolic issues of medicines used for bipolar disorder |
| Q34543946 | Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management |
| Q37724188 | Wnt and the Wnt signaling pathway in bone development and disease |
| Q83588890 | Wnt signaling as a therapeutic target for bone diseases |
| Q37561706 | Wnt signaling during fracture repair |
| Q35560309 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. |
Search more.